About Neuropore
Neuropore is a Healthcare company based in San Diego (United States) founded in 2008. Developer of small molecule therapies for treating neurodegenerative diseases. The company has 10 employees. Neuropore offers products and services including UCB0599, TLR2 Program, and Anti-Oligomerization Program. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is NEUROPORE THERAPIES, INC. Its competitors include Biogen, Denali Therapeutics and Annexon; 3 of its 3 listed competitors have raised funding.
Company details
Neuropore Therapies was founded in 2008 and is based in San Diego, United States. Small molecule therapies for neurodegenerative diseases are developed by the company through computational molecular modeling tools. The lead candidate, UCB0599, an alpha-synuclein oligomerization inhibitor, is being advanced in collaboration with UCB Pharma. This candidate is currently in phase I clinical trials for Parkinsons disease, with investigations focused on disease modification.
- Headquarters San Diego, United States
- Employees 10
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website neuropore.com
- Social LinkedIn X Facebook
- Legal Name Neuropore Therapies, Inc.
- Latest Funding Round$4.8M (USD), Grant
Apr 2022
- InvestorsThe Michael J. Fox Foundation
& 1 more
- Employee Count10
Products & Services of Neuropore
Neuropore offers a comprehensive portfolio of products and services, including UCB0599, TLR2 Program, and Anti-Oligomerization Program.
Phase 2 clinical trial drug for early-stage Parkinson's disease.
Focuses on targeting neuroinflammation in neurodegenerative diseases.
Develops treatments for protein aggregation in neurological conditions.
Funding Insights of Neuropore
- Total Rounds 2
- Last Round Grant — $4.8M
- First Round $500,000
(Feb 2020)
- Investors Count 2
All 2 funding rounds of Neuropore with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $4.8M | Grant | – | – | |
| Feb 2020 | $500,000 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Neuropore
Neuropore has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation and ALS Association.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
| alsa.org |
Investor details for Neuropore
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neuropore
3 dated milestones of Neuropore across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Neuropore is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Grant, of $4.8M.
Competitors of Neuropore
Neuropore has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and Annexon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases |
Detailed competitors of Neuropore
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neuropore
Websites that share an audience with Neuropore (neuropore.com).
Websites whose visitors overlap most with Neuropore. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ichorms.com | 100% | 5.3K | #8,265,520 | View details | |
tiger-aesthetics.com | tiger-aesthetics.com | 98% | #3,583,261 | – | |
| revamedical.com | 97% | 3K | #5,706,387 | View details | |
| passport-tech.com | 97% | 1K | #15,279,178 | View details | |
kadencehealthcare.com | kadencehealthcare.com | 96% | #7,313,283 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 38 similar websites and full traffic analytics for Neuropore
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 38 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Neuropore (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neuropore
Complete news archive for Neuropore
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neuropore
Neuropore was founded in 2008 and raised its 1st funding round 12 years after it was founded.
Neuropore is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Neuropore has 10 employees.
Neuropore Therapies was founded in 2008 and is based in San Diego, United States. Small molecule therapies for neurodegenerative diseases are developed by the company through computational molecular modeling tools. The lead candidate, UCB0599, an alpha-synuclein oligomerization inhibitor, is being advanced in collaboration with UCB Pharma. This candidate is currently in phase I clinical trials for Parkinsons disease, with investigations focused on disease modification.
Neuropore's top competitors include Annexon, Denali Therapeutics and Biogen.
Neuropore offers UCB0599, TLR2 Program, and Anti-Oligomerization Program.
Neuropore has 2 investors. Key investors include The Michael J. Fox Foundation, and ALS Association.
Neuropore operates through Neuropore Therapies, Inc..